Review
Oncology
Tadahiro Shoji, Shunsuke Tatsuki, Marina Abe, Hidetoshi Tomabechi, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa Baba, Hiroaki Itamochi
Summary: Ovarian clear cell and mucinous carcinomas show lower sensitivity to chemotherapy, leading to a poor prognosis. Recent focus has shifted to molecular target drugs and immune checkpoint inhibitors for treatment, with many clinical studies planned. Challenges include finding the best treatment combinations, identifying patients who will benefit from each therapy, and integrating results into standard care for these carcinomas.
Article
Oncology
Jianxiong Li, Huaguo Liang, Wentao Xiao, Peng Wei, Hongmei Chen, Zexin Chen, Ruihui Yang, Huan Jiang, Yongli Zhang
Summary: Through whole-exome sequencing, it was found that CCDC170 gene is closely associated with the survival and prognosis of ovarian cancer. High expression of CCDC170 can significantly prolong the overall survival of ovarian cancer patients, and its expression in ovarian cancer cells is significantly lower than that in normal cells.
Article
Oncology
Michael-John Devilin, Rowan Miller, Florian Laforets, Panoraia Kotantaki, Dale W. Garsed, Rebecca Kristeleit, David D. Bowtell, Jacqueline McDermott, Eleni Maniati, Frances R. Balkwill
Summary: The tumor microenvironment (TME) of clear-cell ovarian cancer (CCOC) was analyzed in this study, revealing differences in immune cell populations, collagen matrix, and cytokine expression between different areas of the tumor. Advanced CCOC showed increased fibroblasts and a more complex collagen matrix compared to early CCOC. Differences in immune cell populations, collagen matrix, and cytokine expression were also observed between different genetic subtypes of CCOC. Increased infiltration of specific T cell subpopulations was associated with decreased overall survival.
CANCER IMMUNOLOGY RESEARCH
(2022)
Editorial Material
Oncology
Stephanie Lheureux
Summary: The diagnosis of clear cell ovarian cancer relies on expert histopathology review. Further characterization through deep genomic and transcriptomic analyses can identify different subgroups. International collaboration is required to define the clinical impact and therapy opportunities in these specific subclassifications.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Satoe Fujiwara
Summary: Ovarian clear cell carcinoma (OCCC) is a rare and distinct type of epithelial ovarian cancer with unique histopathological, clinical, and genetic features. It is associated with younger age at diagnosis and earlier stages compared to the most common type of ovarian cancer. OCCC is considered to have endometriosis as a direct precursor, and the most frequent gene mutations in OCCC are AT-rich interaction domain 1A and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha. Patients with early-stage OCCC have a favorable prognosis, while those at advanced stages or with recurrent disease have a poor prognosis due to the resistance of OCCC to standard platinum-based chemotherapy. Aggressive cytoreductive surgery and adjuvant platinum-based chemotherapy are the recommended treatment strategies, but alternative therapies based on OCCC's specific molecular characteristics are urgently needed. Well-designed international clinical trials are necessary to improve outcomes and quality of life for patients with OCCC.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Adam J. Ferrari, Priyanka Rawat, Hannah S. Rendulich, Akshaya Annapragada, Yasuto Kinose, Xiaoming Zhang, Kyle Devins, Anna Budina, Robert B. Scharpf, Marilyn A. Mitchell, Janos L. Tanyi, Mark A. Morgan, Lauren E. Schwartz, T. Rinda Soong, Victor E. Velculescu, Ronny Drapkin
Summary: Epigenetic aberrations, specifically the loss of histone H2B monoubiquitylation (H2Bub1), are associated with the development and progression of clear cell ovarian carcinoma (CCOC). The study identified hypermethylation of RNF40 as a likely mechanism underlying the loss of H2Bub1 in CCOC. Additionally, depletion of H2Bub1 was found to promote cell proliferation and clonogenicity in an endometriosis cell line.
Article
Oncology
Xingtao Long, Rengui Li, Ying Tang, Lingling Yang, Dongling Zou
Summary: This study aimed to investigate the effect of adjuvant chemotherapy on patients with stage I mucinous ovarian cancer (MOC) undergoing fertility-preserving surgery. The results showed that patients aged 31-45, with grade 3 tumors, stage IC disease, and non-fertility-sparing surgery were more likely to receive postoperative chemotherapy. For patients who underwent fertility-sparing surgery, the choice of chemotherapy may increase the risk of death.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Yuki Shiko, Yoshihito Ozawa, Yohei Kawasaki, Makio Shozu
Summary: The study found that incorporating bevacizumab into first-line chemotherapy may improve progression-free survival in patients with advanced clear cell carcinoma.
Article
Oncology
Shuqing Li, Zhiling Zhu
Summary: This study investigated whether chemotherapy is necessary for patients with stage IA ovarian clear cell carcinoma (OCCC). The results showed that chemotherapy did not prolong the overall survival of patients with stage IA OCCC.
Article
Oncology
Fengxian Fu, Xulan Ma, Yiyan Lu, Hongbin Xu, Ruiqing Ma
Summary: This study retrospectively reviewed the clinicopathological characteristics and prognostic factors of 22 patients with MOC-derived PMP, suggesting that histopathologic subtype and PCI may predict prognosis, and patients with high-grade disease may benefit from complete cytoreduction.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Ignacio Vazquez-Garcia, Florian Uhlitz, Nicholas Ceglia, Jamie L. P. Lim, Michelle Wu, Neeman Mohibullah, Juliana Niyazov, Arvin Eric B. Ruiz, Kevin M. Boehm, Viktoria Bojilova, Christopher J. Fong, Tyler Funnell, Diljot Grewal, Eliyahu Havasov, Samantha Leung, Arfath Pasha, Druv M. Patel, Maryam Pourmaleki, Nicole Rusk, Hongyu Shi, Rami Vanguri, Marc J. Williams, Allen W. Zhang, Vance Broach, Dennis S. Chi, Arnaud Da Cruz Paula, Ginger J. Gardner, Sarah H. Kim, Matthew Lennon, Kara Long Roche, Yukio Sonoda, Oliver Zivanovic, Ritika Kundra, Agnes Viale, Fatemeh N. Derakhshan, Luke Geneslaw, Shirin Issa Bhaloo, Ana Maroldi, Rahelly Nunez, Fresia Pareja, Anthe Stylianou, Mahsa Vahdatinia, Yonina Bykov, Rachel N. Grisham, Ying L. Liu, Yulia Lakhman, Ines Nikolovski, Daniel Kelly, Jianjiong Gao, Andrea Schietinger, Travis J. Hollmann, Samuel F. Bakhoum, Robert A. Soslow, Lora H. Ellenson, Nadeem R. Abu-Rustum, Carol Aghajanian, Claire F. Friedman, Andrew McPherson, Britta Weigelt, Dmitriy Zamarin, Sohrab P. Shah
Summary: This study provides insights into the relationship between mutational processes, anatomical sites, and immune resistance mechanisms in HGSOC, highlighting the importance of personalized immunotherapeutic approaches and early detection research.
Article
Oncology
Jennifer X. Ji, Dawn R. Cochrane, Gian Luca Negri, Shane Colborne, Sandra E. Spencer Miko, Lynn N. Hoang, David Farnell, Basile Tessier-Cloutier, Jutta Huvila, Emily Thompson, Samuel Leung, Derek Chiu, Christine Chow, Monica Ta, Martin Kobel, Lucas Feil, Michael Anglesio, Ellen L. Goode, Kelly Bolton, Gregg B. Morin, David G. Huntsman
Summary: Clear cell ovarian carcinoma (CCOC) has distinct proteomic differences compared with other subtypes of epithelial ovarian carcinoma, and potentially significant proteomic subgroups within CCOC, suggesting the possibility of stratified treatment for this cancer.
JOURNAL OF PATHOLOGY
(2022)
Review
Oncology
Ryo Tamura, Kosuke Yoshihara, Takayuki Enomoto
Summary: Ovarian clear cell carcinoma (OCCC) is characterized by chemotherapy resistance and poor prognosis, especially in advanced cases. This review focuses on the association between cancer-associated hypercoagulation and molecular biology in OCCC. Additionally, potential drug therapies targeting hypercoagulation for OCCC are summarized. The review is expected to contribute to novel research and trials for the prevention, early detection, and treatment of OCCC.
Article
Oncology
Emer O'Connell, Ian S. Reynolds, Andreas U. Lindner, Manuela Salvucci, Tony O'Grady, Orna Bacon, Sanghee Cho, Elizabeth McDonough, Daniel Longley, Fiona Ginty, Deborah A. McNamara, John P. Burke, Jochen H. M. Prehn
Summary: Apoptotic and necroptotic mediators are differentially expressed in mucinous and non-mucinous colorectal cancers, suggesting potential targets for investigating cell death mechanisms in the mucinous subtype.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Meifu Gan, Zaixian Tai, Yijian Yu, Chao Zhang, Juan Xu
Summary: Ovarian clear cell carcinoma (OCCC) is a special type of epithelial ovarian cancer closely related to endometriosis and endometrial clear cell carcinoma (ECCC). A study using next-generation sequencing analysis compared the genomic features of OCCC with high-grade serous ovarian carcinoma (HGSOC) and ECCC. The study identified high-frequency mutations in ARID1A and PIK3CA in OCCC and revealed distinct mutational signatures across different types of ovarian cancer. Additionally, novel copy number variation events were identified in OCCC. This study provides insights into the tumorigenesis of OCCC and potential therapeutic targets.
Article
Biochemistry & Molecular Biology
Evangelos Terpos, Vangelis Karalis, Ioannis Ntanasis-Stathopoulos, Zoi Evangelakou, Maria Gavriatopoulou, Maria S. Manola, Panagiotis Malandrakis, Despoina D. Gianniou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A. Dimopoulos
Summary: This study compared the neutralizing antibody levels after vaccination with BNT162b2 mRNA vaccine and ChAdOx1 (AZD1222) viral vector vaccine at different time points. The results showed that BNT162b2 induced stronger neutralizing antibody responses compared to AZD1222, and both vaccines showed a gradual decline in antibody titers over time. Additionally, the rate of antibody elimination was higher in those vaccinated with AZD1222 compared to BNT162b2. Age, gender, body mass index, or comorbidities did not significantly impact antibody levels over time.
Article
Oncology
Aristotelis Bamias, Axel Merseburger, Yohann Loriot, Nicholas James, Ernest Choy, Daniel Castellano, F. Lopez-Rios, Fabio Calabro, Mario Kramer, Guillermo de Velasco, Roubini Zakopoulou, Kimon Tzannis, Cora N. Sternberg
Summary: An improved prognostic model was developed for patients with advanced urothelial cancer receiving second-line atezolizumab. This model provides better prediction of overall survival compared to the traditional Bellmunt Risk Score algorithm and can assist in guiding the selection of patients for second-line immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Vasiliki Gkalea, Despina Fotiou, Meletios Athanasios Dimopoulos, Efstathios Kastritis
Summary: It is increasingly recognized that patients with monoclonal gammopathy (MG) who do not meet criteria for malignant disease and treatment initiation may have other manifestations that are clinically significant and could provide a rationale for treatment. These patients are at higher risk for thrombosis, including venous, arterial, and micro-thrombotic events. The challenge is to identify high-risk MG patients for thrombotic events and apply appropriate preventive measures.
Article
Oncology
Dimitra Rafailia Bakaloudi, Rafee Talukder, Genevieve Ihsiu Lin, Dimitrios Makrakis, Leonidas N. Diamantopoulos, Nishita Tripathi, Neeraj Agarwal, Roubini Zakopoulou, Aristotelis Bamias, Jason R. Brown, David J. Pinato, James Korolewicz, Tanya Jindal, Vadim S. Koshkin, Jure Murgic, Marija Miletic, Ana Frobe, Jeffrey Johnson, Yousef Zakharia, Alexandra Drakaki, Alejo Rodriguez-Vida, Macarena Rey-Cardenas, Daniel Castellano, Lucia Alonso Buznego, Ignacio Duran, Clara Castro Carballeira, Rafael Morales Barrera, David Marmorejo, Rana R. McKay, Tyler Stewart, Shilpa Gupta, Andrew Thomas Ruplin, Evan Y. Yu, Ali R. Khaki, Petros Grivas
Summary: This study retrospectively observed the clinical features and outcomes of aUC patients receiving avelumab maintenance treatment. The results showed that prior response to platinum-based chemotherapy, ECOG PS 0, and absence of liver metastases were favorable prognostic factors.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Medicine, General & Internal
Ioannis Rodolakis, Vasilios Pergialiotis, Michalis Liontos, Dimitrios Haidopoulos, Dimitrios Loutradis, Alexandros Rodolakis, Aristotelis Bamias, Nikolaos Thomakos
Summary: The chemotherapy response score is a predictive index for survival outcomes in advanced-stage epithelial ovarian cancer patients undergoing interval debulking surgery. However, its accuracy in determining patients with a shorter overall survival is still debated and there is a need for standardization of the scoring system. Research should also focus on the predictive value of determining patients with platinum resistance to identify those at risk of recurrence. This review provides a summary of current knowledge and suggests directions for future research.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Vassiliki Spiliopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou
Summary: This study assessed the effectiveness and tolerability of belantamab mafodotin in triple-class refractory patients with multiple myeloma. It showed promising results in some patients and had manageable toxicity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Nutrition & Dietetics
Melpomeni Peppa, Aspasia Manta, Ioanna Mavroeidi, Constantinos Nastos, Emmanouil Pikoulis, Konstantinos Syrigos, Aristotelis Bamias
Summary: Hormone-related cancers are dependent on hormone levels that play an essential role in cancer growth. Diet, along with traditional risk factors, seems to be an important environmental factor that explains the increased prevalence of these cancers. Carbohydrates, specifically glycemic index and glycemic load, are implicated as risk factors for hormone-related cancers by affecting insulin metabolism and inducing inflammation and oxidative stress. This article reviews existing data on the impact of diets focusing on glycemic index and glycemic load estimates on hormone-related cancers.
Article
Oncology
Angeliki Andrikopoulou, Charalampos Theofanakis, Christos Markellos, Maria Kaparelou, Konstantinos Koutsoukos, Kleoniki Apostolidou, Nikolaos Thomakos, Dimitrios Haidopoulos, Alexandros Rodolakis, Meletios-Athanasios Dimopoulos, Flora Zagouri, Michalis Liontos
Summary: The optimal time interval between neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) in high-grade serous ovarian carcinoma (HGSC) is unclear. A retrospective study was conducted on HGSC patients who underwent NACT followed by IDS in a 15-year period. The study found that performing IDS within four weeks after NACT was associated with better survival outcomes. Multivariate analysis showed that a short time interval (<4 weeks) from NACT to IDS was an independent factor of both PFS and OS.
Article
Oncology
Lisa B. Leypoldt, Maria Gavriatopoulou, Britta Besemer, Hans Salwender, Marc S. Raab, Axel Nogai, Cyrus Khandanpour, Volker Runde, Anna Jauch, Manola Zago, Peter Martus, Hartmut Goldschmidt, Carsten Bokemeyer, Meletios A. Dimopoulos, Katja C. Weisel
Summary: This study evaluated the safety and efficacy of daratumumab, bortezomib, and dexamethasone in multiple myeloma patients with severe renal function impairment. The treatment showed an overall response rate of 67% and improved renal function in patients. This study suggests that this treatment regimen could be considered in the clinical practice for multiple myeloma patients with severe renal function impairment.
Review
Oncology
Ioanna E. Stergiou, Stavros P. Papadakos, Anna Karyda, Ourania E. Tsitsilonis, Meletios-Athanasios Dimopoulos, Stamatios Theocharis
Summary: The EPH/ephrin signaling axis plays a crucial role in both embryonic development and adult life, and recent studies have shown its involvement in the pathogenesis of various types of solid tumors. In normal hematopoiesis, different patterns of EPH/ephrin expression are associated with the maintenance, differentiation, and function of hematopoietic stem cells and their mature offspring. Abnormalities in the EPH/ephrin pathway have been found to contribute to the development of hematologic malignancies, with both tumor-promoting and tumor-suppressive effects. Understanding the complexity of this signaling pathway in normal and malignant hematopoiesis is essential for the development of potential therapeutic targets.
Review
Urology & Nephrology
Aristotelis Bamias, Arnulf Stenzl, Flora Zagouri, Angeliki Andrikopoulou, Peter Hoskin
Summary: Unlike other cancers, there is a lack of systematic investigation on oligometastatic disease (OMD) in bladder cancer (BC). This article aims to assist in developing a definition of oligometastatic BC (OMBC) and providing recommendations on staging and local therapies through a systematic review.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)
Review
Medicine, General & Internal
Efstathia Liatsou, Ioanna Tatouli, Andreas Mpozikas, Maria-Markella Pavlou, Hariklia Gakiopoulou, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Sofoklis Kontogiannis, Meletios Athanasios Dimopoulos
Summary: Tenofovir disoproxil fumarate (TDF) is a drug used to treat patients with HIV and HBV infections, but it may cause acute renal failure and Fanconi syndrome in a few cases. The risk of renal toxicity in HBV patients appears to be low, but kidney function should still be monitored.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Alexander Georgakopoulos, Aristotle Bamias, Sophia Chatziioannou
Summary: PSMA PET/CT has emerged as a promising diagnostic imaging tool for the diagnosis and management of PC. It improves the detection of clinically significant PC and is more accurate than CT and bone scan in the initial staging.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Ioanna Barla, Panagiotis Efentakis, Sofia Lamprou, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Evangelos Terpos, Ioanna Andreadou, Nikolaos Thomaidis, Evangelos Gikas
Summary: The antineoplastic agent carfilzomib (Cfz) is used to treat multiple myeloma; however, it can cause cardiotoxicity and nephrotoxicity as common adverse effects. While the mechanisms of these side effects are well-established, there is limited research on the drug's metabolic alterations and their impacts.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, Research & Experimental
Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Vassiliki Spiliopoulou, Rodanthi-Eleni Syrigou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Roussou, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Evangelos Terpos
Summary: Tixagevimab/cilgavimab (Evusheld) appears to be beneficial for high-risk immunocompromised patients with multiple myeloma in preventing COVID-19. Administration of the drug resulted in increased neutralizing-antibody levels and a low incidence of COVID-19, with no new safety concerns emerging.